Incyte
Illumina Announces Layoffs as Incyte Forges AI Partnership for Drug Discovery
Illumina, layoffs, Incyte, Genesis Therapeutics, AI partnership, drug discovery, GEMS platform, small molecule therapeutics
Cancer Pipelines Contract: Incyte and iTeos Discontinue Drug Candidates Amid Underwhelming Clinical Results
Incyte, iTeos, cancer pipelines, drug candidates, clinical trials, disappointing data, pipeline cuts, oncology research.
Incyte Unveils Promising Monjuvi Data at ASH24, Paving Way for FDA Label Expansion in Follicular Lymphoma
Incyte, Monjuvi, ASH24, Follicular Lymphoma, Label Expansion, FDA, Phase 3 Trial
Incyte’s $750M Acquisition Hits Roadblock: Key Trial Paused and Asset Cull Announced
Incyte, $750M buyout, paused trial, asset cull, biotech news, pharmaceutical industry
Incyte’s PD-1 Drug Zynyz: A Strategic Pipeline Component Despite Recent Trial Success
Incyte, Zynyz, PD-1 inhibitor, anal cancer, pipeline strategy, clinical trials, FDA approval
Incyte Seeks Expanded Approval for Monjuvi Following Successful Phase III Trial in Follicular Lymphoma
Incyte, Monjuvi, follicular lymphoma, Phase III trial, label expansion, tafasitamab, MorphoSys, FDA approval, cancer treatment.
Incyte and Syndax Secure FDA Approval for Niktimvo, a Breakthrough Treatment for Chronic Graft-Versus-Host Disease
Incyte, Syndax, Niktimvo, FDA approval, graft-versus-host disease, GVHD, axatilimab-csfr, chronic GVHD, allogeneic stem cell transplant
Incyte Discontinues Five Early-Stage Oncology Programs in Pipeline Refocus
Incyte, cancer pipeline, oncology programs, PD-L1 inhibitors, strategic review, R&D refocus
Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials
Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer
Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition
Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million